RPAM
MLYS icon

Rhenman & Partners Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
416,371
+153,300
+58% +$4.21M 1.06% 42
2026
Q1 		$7.13M Buy
263,071
+120,500
+85% +$3.53M 0.88% 47
2025
Q4 		$5.17M Sell
142,571
-22,429
-14% -$899K 0.48% 64
2025
Q3 		$6.26M Buy
+165,000
New +$3.57M 0.69% 46

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rhenman & Partners Asset Management's MLYS Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Mineralys Therapeutics (MLYS) stake by 58% in Q2 2026, buying an estimated $4.21M and bringing the position to 416,371 shares worth $11.2M. The position accounts for 1.06% of the portfolio, ranked #42.

Rhenman & Partners Asset Management first reported a position in MLYS in Q3 2025 and has held it in 4 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Rhenman & Partners Asset Management held 416,371 shares of Mineralys Therapeutics worth $11.2M as of Q2 2026.
  • Rhenman & Partners Asset Management bought 153,300 Mineralys Therapeutics shares in Q2 2026, an estimated $4.21M.
  • Mineralys Therapeutics made up 1.06% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #42 holding.
  • Rhenman & Partners Asset Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.